On March 7, 2019 FDA updated the Center for Drug Evaluation and Research (CDER) Manual of Policies on Procedures (MAPP) for Nonproprietary Naming of Biological Products. The material is referred to as MAPP 6720.5.
This material describes procedures for handling requests for nonproprietary name suffix review for INDs and BLAs for originator biological products, related biological products, and biosimilar products to be used in the CDER. Reference is made to the final FDA guidance issued in January of 2017 regarding nonproprietary naming of biological products, which notes that the nonproprietary name designated for each originator biological product, related biological product, and biosimilar product is a proper name that is a combination of the core name and a distinguishing suffix that is: (1) designated by FDA, (2) devoid of meaning, and (3) composed of four lowercase letters.
In particular, Division of Medication Error Prevention and Analysis (DMEPA) officials in the Office of Surveillance and Epidemiology (OSE) are authorized to take regulatory actions related to the approval of drugs for human use that are the subject of a BLA under CDER jurisdiction, including decisional letters regarding review of the nonproprietary name suffix candidate. The policy and procedure material discusses the responsibilities of various offices within the CDER regarding review of nonproprietary name suffixes identified by FDA or proposed by a sponsor. Some designated responsibilities are as follows:
More information regarding nonproprietary naming of biological products can be found here. The material additionally may be applicable to interchangeable biological products as discussed in a recent FDA guidance.
Readers are encouraged to read MAPP 6720.5, also available on FDA’s website.
November 4-5, 2020
July 10, 2020
May 5-6. 2020
April 8, 2020
April 3, 2020
March 30-31, 2020
March 22-26, 2020
March 19, 2020
March 15-18, 2020